Topic Archives: lung cancer

Comments

  • Avatar

    Great article Doc. Any thoughts on Tagrisso: "In a clinical study, people taking TAGRISSO for metastatic non-small ce...

  • Avatar

    I reply to this comment specifically. The "CARCINOGENS IN MARIJUANA SMOKE" are to a large extent overcome in the user b...

  • Avatar

    Genprex, Inc. (GNPX) - Rodney Varner, Chairman and CEO, remarked during the recent Clinical and Corporate Update for Sec...

  • Gr8Full!

    Please #StandWithMe in #Actions & #Prayers that my #BrotherInChrist, Charles Hielscher IS #HEALED, MADE Whole In The Na...

  • Avatar

    Yeah, but the 5 year survival rate for non-early stage lung cancer is still a joke. Over the past 35 years I have lost ...

  • Gr8Full!

    $SIX:MOLN > INTERIM MANAGEMENT STATEMENT Q1 2018 http://e1.marco.ch/publish/konsulenten/8f7bfe72/tner_interest_underlin...

  • Gr8Full!

    #EndPoints Early Edition NEW Novartis poaches Bristol-Myers/Amgen vet John Tsai for top drug development post in a ...

  • Gr8Full!

    $HTBX - Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Sm...

  • Gr8Full!

    $HTBX - Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phas...

  • Avatar

    Most of the potheads I knew that died didn't die of cancer. They died of liver disease from alcohol. It's a horrible d...

  • Avatar

    $HTBX long Some Salient points regarding Heat biologics 1) The company is evaluating the lead product 110 in combin...

  • Avatar

    $HTBX LONG 30-Jan-2018:07:00:00, Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Re...

  • Avatar

    $NT. Dr. KSS. About 30 years ago a Dr. client of mine who smoked got lung cancer and told me he was going to beat it wi...

  • SoGiAm

    NEW Looking for a come-from-behind win, Roche touts its pivotal success for Tecentriq combo in front-line lung cancer...

  • SoGiAm

    $HTBX #HeatBiologics Receives #FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Ce...

  • Dr. KSS MD PhD

    Abivax shares under pressure this morning on news being reported by Bloomberg that a lung cancer patient treated with $B...

  • SoGiAm

    $TRIL - Society for Neuro-Oncology 22nd Annual Meeting poster: http://s2.q4cdn.com/772010778/files/doc_presentations/20...

  • Avatar

    I had lung cancer, got it treated with the Cyberknife of Accuray, and have been cancer free for two years now. The treat...

  • Avatar

    $SNDX LONG second at peak 04:40 SNDX Syndax Pharmaceuticals presents ENCORE 601 data that continues to support...

  • Avatar

    $RXDX A nice interview with Ignyta’s CEO, Dr. Jonathan Lim, published in Rare Disease Report on November 8. Some Gu...

  • Avatar

    $HALO From their report: "In November 2015, we initiated a Phase 1b study exploring the combination of PEGPH20 and KEY...

  • SoGiAm

    $TRIL - November 18, 2017 05:00 PM PST San Francisco, CA Presenter: Zezhou Wang, Ph.D., Trillium Research Scientist h...

  • SoGiAm

    Tiny Ignyta's Lung Cancer Drug Bested Pfizer's. Probably. Will We Ever Know For Sure? https://www.forbes.com/forbes/wel...

  • SoGiAm

    $LUNG - PROLUNG SETS TERMS FOR $7 MILLION IPO October 17, 2017 ProLung, which is developing a test that predicts early...

  • SoGiAm

    RXDX - Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therap...

  • Avatar

    RXDX long Ignyta has updated ongoing Phase 2 data for entrectinib. The results appear to be very positive and in lin...

  • Avatar

    Long $ MRTX Mirati Therapeutics price target raised to $20 from $13 at SunTrust SunTrust analyst Peter Lawson rais...

  • Avatar

    Long. $Rxdx Follow to Ling Ling Post Ignyta Highlights from Our KOL Call on the ROS1 / TRK Space - ALERT Last we...

  • Avatar

    $RXDX Ignyta’s (RXDX) Buy Rating Reaffirmed at J P Morgan Chase & Co, PT=$20 Friday, October 13th, 2017 J P...

  • Avatar

    $MRTX Mirati Therapeutic’s Mocetinostat was selected to participate in the prestigious SU2C program to bring cuttin...

  • SoGiAm

    $BIOC - Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board http://www.prne...

  • Avatar

    $ MRTX LONG Mirati Therapeutics data likely to be positive, says SunTrust SunTrust analyst Peter Lawson believes...

  • SoGiAm

    $RXDX - Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on...

  • Avatar

    $MRTX More details about the Oppenheimer coverage: "Oppenheimer analyst Leah R. Canninitiated coverage with a Buy...

  • Avatar

    $MRTX Doc, many thanks for your insightful comments. As I understand it the detailed data set will be, or has been, r...

  • SoGiAm

    $MTRX np - Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-S...

  • Avatar

    $RXDX (Great new data! RXDX up 9.5% in PM) Ignyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Co...

  • SoGiAm

    $RXDX - Ignyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Congress http://www.businesswire.com/news/...

  • SoGiAm

    $RXDX - gnyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program https://ignyta.com/investo...

  • SoGiAm

    $RXDX - Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017 SAN DI...

  • Avatar

    $RXDX long. Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017 SA...

  • Avatar

    I smoked from teenage years until 1989 and kept having trouble with my tonsils every year i was diagnosed with asymmetri...

  • SoGiAm

    $BIOC np - Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lun...

  • Avatar

    $TRIL $CD47 Ladenburg report on Trillium's 2nd quarter: (8/12) In excerpts: 2Q17 Results. TRIL reported a net lo...

  • SoGiAm

    New genes discovered regulating brain metastases in lung cancer patients https://www.sciencedaily.com/releases/2017/08/...

  • SoGiAm

    $KALA ? np - Protein nanocages that penetrate airway mucus and tumor tissue http://www.pnas.org/content/114/32/E6595.a...

  • SoGiAm

    $RXDX long - https://ignyta.com/investors/press-release-article/1036548/ Company Highlights Updated Progress Towar...

  • Dr. KSS MD PhD

    We've said it before: PD-1 checkpoint inhibitors ARE NOT created equal though they "seem" to act on the same pathway. Ca...

  • Avatar

    $SNDX- Yes this is 2 separate data readouts. SNDX's Entinostat has a breast cancer trial going on as well as an Imunoonc...

  • Avatar

    $TRIL Trillium Provides Update on Small Molecule Programs In excerpts: "Trillium has applied its unique medicin...

  • Avatar

    The latest in precision medicine for lung cancer. http://blog.aacr.org/fda-approves-new-lung-cancer-treatment-and-first...

  • Avatar

    Todd, I just read your post on the main thread, and I am so glad for you to hear of such hope for your wife's cure. It...

  • Avatar

    A close friend of mine has ALK lung cancer. Do you know of any biotechs Working on this cancer?...

  • Avatar

    $AFMD Long - sorry for the long post but it took me awhile to locate the abstracts so I thought I'd post for others who ...

  • Avatar

    I need to take my daughter to the dentist, but wanted to throw this out there--yesterday (or this morning?) $VBLT releas...

  • Avatar

    Another political scam. Big Tobacco money was supposed to help victims fight lung cancer and other medical conditions...

  • Avatar

    $TRIL: a recent report from Ladenburg Thalmann, post-ASCO17 TRILLIUM THERAPEUTICS INC. TTI-621 Expands Several New...

  • Avatar

    $LOXO: Paradigm shift's afoot at Biotech's most prestigous conference ASCO17 with Gene-targeted or "tissue agnostic" whe...

  • Avatar

    Thanks Doc. I do have a question (or series of questions), but it is/they are so basic that I am wary about taking up ev...

  • Avatar

    $SNDX Syndax Pharmaceuticals (SNDX): Early Ph2 Data Encouraging - Citi's new TP=>$24 May 18, 2017 7:25 AM Ci...

  • Avatar

    $SNDX Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD...

  • Avatar

    $ VBLT Long 11-May-2017:07:00:00, VBL Therapeutics Presents Data on VB-111 in Combination with Checkpoint Inhibitor...

  • SoGiAm

    $BIOC long - The Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of Landmark ALC...

  • arch1

    $BIOC news,,,I apologize if this has been posted. Seems long term agreement with $CPRX to test small cell lung cancer pa...

  • SoGiAm

    $BIOC long - Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Canc...

  • Avatar

    $TSRO: TESARO Announces Fourth-Quarter 2016 Operating Results (2/28) HIGHLIGHTS: --Niraparib: NDA under review ...

  • Myron Martin

    I am sorry if I offended you Dave, I never knew your grandmother, so I was not casting aspersions on her lifestyle, but ...

  • Avatar

    $RXDX Long. Ignyta continues to climb, up another 10% today ($9.35). I have no special insight into long-term valuation ...

  • Avatar

    $CLRB long my first post here, asking for some insights to understand each segments of their business better. 1. live...

  • Avatar

    Gild: ''Gilead Sciences (GILD): 'Acquisition Wanted! - Please Apply Within' Following its 'kitchen sink' HCV guidance a...

  • Avatar

    Hi Doc, Thanks for the information. Again, I am skeptical, this one violates my "well-traveled drug" rule. It was approv...

  • Avatar

    Hi I have lung cancer been doing treatment no longer working would like to try this alpha cells treatment...

  • Dr. KSS MD PhD

    Bristol has abandoned plans to study nivolumab and Yervoy in lung cancer. But is not saying why so as "to protect the in...

  • Avatar

    Bloomberg's take on this development: "Bristol-Myers Falls Further Behind Merck in Lung Cancer Race" The shares fe...

  • Avatar

    Hi Everyone, FDA locked the gate on $BMY front-line lung cancer Tx. (Opdivo + Yervoy Accelerated pathway abandoned) in...

  • SoGiAm

    News report: Study suggests small cell lung cancer should not be treated as single disease http://www.cancerresearchuk....

  • Avatar

    Biotech is our chance for real cures, IMO - such as for cancer. My poor brother has small cell lung cancer, and if the...

  • Avatar

    A new research report on $MRK issued by BMO Capital on 1/10/17: "In Position to Meaningfully Strengthen Leadership ...

  • Avatar

    Berberine. Here is what I found at LEF.Com. Berberine is an alkaloid found in various different medicinal herbs. Prob...

  • SoGiAm

    $BIOC long and so is this post: Biocept Presents Robust Analytical Validation Study Results for its PD-L1 Liquid Biop...

  • SoGiAm

    PD-1 protein could serve as biomarker for predicting survival of lung cancer patients https://twitter.com/weldeiry/stat...

  • Avatar

    Thanks, Blue. Great article. Cimavax was developed to combat the high rate of lung cancer, which is understandable given...

  • Avatar

    I note that the NY Times and other papers have articles regarding cimavax, a Cuban vaccine to slow development of lung c...

  • SoGiAm

    CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer. http://www.sigmaaldrich.com/catalog/papers/27...

  • Avatar

    My brother was on nivolumab (lung cancer) and was taken off after having some of the more severe symptoms, and is still...

  • Avatar

    Merck with Keytruda wins early US approval with those with untreated lung cancer. http://www.reuters.com/article/us-m...

  • JohnM

    $BIOC no position. Good news. Biocept announces that clinical results from a study evaluating 40 patients with advanc...

  • Avatar

    $BMY's opdivo is still a good drug and valuable asset to the company, but data released since summer and confirmed last ...

  • Avatar

    I'm confused as to the recent Opdivo (nivolumab) conflicting news. One report says that this $BMY immunotherapy is a ga...

  • SoGiAm

    $BIOC - Clinical Results Demonstrating the Performance of Biocept's Target Selector Platform to be Presented at the 2016...

  • SoGiAm

    $KPTI - Karyopharm Publishes Preclinical Data in Nature Demonstrating Selinexor's Potential in KRAS-Mutant Non-Small Cel...

  • Avatar

    $RXDX - an interesting new article on Ignyta that provides excellent insights into the company’s past, present. and fu...

  • Avatar

    When Breath Becomes Air by Paul Kalanithi is an amazing book about death. "At the age of thirty-six, on the verge of...

  • SoGiAm

    Checkpoint Inhibitors and Combination Therapy: the Future of Treatment for Non-small Cell Lung Cancer? https://twitter....

  • Avatar

    Back in February I bought the US version of Pharmamar with symbol PHMMF. It tracks the Madrid version . I paid $2.60 an...

  • Dr. KSS MD PhD

    For yesterday's QOD, the question was about which form of clinical pain is most severe. It was a Torquemada-like questio...

  • SoGiAm

    Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibito...

  • Dr. KSS MD PhD

    A conservative biotech investing idea. Readers might want to consider a trading buy into $BMY here, oversold after its (...

  • Dr. KSS MD PhD

    Answer to today's question. To treat bacterial infections, the first step is to have in mind what flavor of pathogen ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch